Back to Search
DANIEL REECE, DMD, MD
DMD, MD
Oral and Maxillofacial Surgery (Dentist)
NPI: 1306229893Individual
Specialties, Licenses & Credentials
Dentist
Dentist
Code: 122300000X
30.024543(OH)
Oral and Maxillofacial Surgery (Dentist)Primary
Dentist — Oral and Maxillofacial Surgery
Code: 1223S0112X
DR.0063630(CO)DEN.00204273(CO)
Research & Publications (20)
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
PMID 19332768·Blood·2009
3-trial
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
PMID 18645194·J Clin Oncol·2008
3-trial
Hematopoietic stem cell transplantation in Hodgkin disease.
PMID 11880706·Curr Opin Oncol·2002
6-review
1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
PMID 19448682·Bone Marrow Transplant·2010
8-other
Recent trends in the management of newly diagnosed multiple myeloma.
PMID 19491669·Curr Opin Hematol·2009
6-review
Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.
PMID 18676019·Leuk Res·2009
8-other
Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study.
PMID 19362968·Clin Lymphoma Myeloma·2009
4-observational
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
PMID 19225538·Leukemia·2009
3-trial
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
PMID 19170677·Br J Haematol·2009
3-trial
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
PMID 19545290·Br J Haematol·2009
8-other
Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
PMID 19450753·Biol Blood Marrow Transplant·2009
8-other
Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit.
PMID 18936734·Bone Marrow Transplant·2009
8-other
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
PMID 19498019·Blood·2009
3-trial
Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.
PMID 19322205·Leukemia·2009
4-observational
Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation.
PMID 18804043·Biol Blood Marrow Transplant·2008
4-observational
A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma.
PMID 18381234·Cancer Treat Rev·2008
1-meta
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
PMID 18711175·J Clin Oncol·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 1199 Village Rd Ste 203
Carbondale, CO 81623 - Phone
- (970) 245-2222
Quick Facts
- NPI
- 1306229893
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile